Expression vector of FLAG-tagged human Mint3 gene mutant.
| Clone info. | Expression vector of FLAG-tagged human Mint3 gene mutant; deletion of containing phosphotyrosine-binding (PTB) domains (215-364), see Fig. 5C for details. |
|---|---|
| Comment | Expression was confirmed by the depositor with immunoprecipitation. Known difference: G to A substitution at 2,389nt (Arg to His at 69aa9 in Zeocin resistance gene (corresponding 2183-2558nt of pCDNA3.1/Zeo(+) plasmid). |
| Vector backbone | pcDNA3 derivative (Plasmid) |
| Selectable markers | Amp^r (E. coli), Zeo^r (mammalian cells). |
| Growth conditions | LB+Amp, 37℃ |
| Gene/insert name | human Mint3 cDNA |
| Depositor|Developer | Sakamoto, Takeharu | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment MTA, for use for not-for-profit academic purpose [Word Please visit Information of Request for Distribution.[link] |
|---|---|
| Terms and conditions for distribution | In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Nakaoka, H.J. et al., Sci. Rep. 6: 22784, 2016) Additional terms and conditions: Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen’s Limited Use Label License applies to your use of this product. |
| Remarks | Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC. Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License. |
[open/close]| 必要書類 | 提供依頼書 提供同意書 (MTA, 非営利学術目的用)[Word 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Nakaoka, H.J. et al., Sci. Rep. 6: 22784, 2016)。 付加的使用条件: InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。 |
| 備考 | Gateway®テクノロジーを用いた発現クローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。 ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。 |
| Catalog # | Resource name | Availability | Shipping form | Fee |
|---|---|---|---|---|
| RDB14318 | pcDNA3.1_V5-Mint3_dPTB-FLAG | Under QC test. Please contact us. | DNA solution |
Materials & Methods section:
| The pcDNA3.1_V5-Mint3_dPTB-FLAG was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB14318). |
Reference section:
| Nakaoka, H.J., Hara, T., Yoshino, S., Kanamori, A., Matsui, Y., Shimamura, T., Sato, H., Murakami, Y., Seiki, M., Sakamoto, T., NECAB3 Promotes Activation of Hypoxia-inducible factor-1 during Normoxia and Enhances Tumourigenicity of Cancer Cells. Sci. Rep, 6: 22784 (2016). PMID 26948053. [PubMed] [Article] [RRC of NBRP] |
Further references such as user reports and related articles (go to bottom)
Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.
Original, user report and related articles
| original | Nakaoka, H.J., NECAB3 Promotes Activation of Hypoxia-inducible factor-1 during Normoxia and Enhances Tumourigenicity of Cancer Cells. Sci. Rep, 6: 22784 (2016). PMID 26948053. [PubMed] [Article] [RRC of NBRP] |
|---|
Featured content